Cost of Revenue: Key Insights for Dyne Therapeutics, Inc. and Xencor, Inc.

Biotech Cost Trends: Dyne vs. Xencor from 2014-2023

__timestampDyne Therapeutics, Inc.Xencor, Inc.
Wednesday, January 1, 2014114500000018516000
Thursday, January 1, 2015202800000034140000
Friday, January 1, 2016228100000051872000
Sunday, January 1, 2017293200000071772000
Monday, January 1, 20182400097501000
Tuesday, January 1, 2019271000118590000
Wednesday, January 1, 2020700000169802000
Friday, January 1, 202110880007491000
Saturday, January 1, 202233450008799000
Sunday, January 1, 20232461000253598000
Loading chart...

Unleashing the power of data

Analyzing Cost of Revenue Trends for Biotech Innovators

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis focuses on the cost of revenue for Dyne Therapeutics, Inc. and Xencor, Inc. from 2014 to 2023. Over this period, Dyne Therapeutics experienced a dramatic fluctuation, with costs peaking in 2017 and then plummeting by over 99% in 2018. This volatility reflects the challenges and strategic shifts in the biotech sector. In contrast, Xencor, Inc. demonstrated a more consistent growth trajectory, with costs increasing steadily by approximately 1,270% from 2014 to 2023. This steady rise suggests a stable expansion strategy. The data highlights the contrasting financial strategies and market responses of these two companies, offering valuable insights for potential investors and industry analysts.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025